Answers are grounded in this paper and cite their sources.
Background: This pilot study aimed to assess the potential of cystatin C (Cys C) as a biomarker in non-Hodgkin lymphoma (NHL) and to explore its association with paraoxonase 1 (PON1) activity. Methods: The study included 44 patients with B-cell NHL and 44 healthy subjects. Cys C was measured using the Cobas e 801 analyser (Roche Diagnostics GmbH, Mannheim, Germany), while PON1 and TAS were measured on the ILab 300+ system (Instrumentation Laboratory, Milan, Italy). Results: The serum level of Cys C (mg/L) was significantly higher in NHL patients compared to control subjects: 1.03 (0.88-1.24) vs 0.83 (0.78-0.90), P<0.001. The diagnostic performance of Cys C, as assessed by the area under the ROC curve (AUC), was 0.812 (95% CI: 0.732-0.902). The optimal cut-off value for Cys C was 0.870 mg/L, with sensitivities and specificities of 77.1% and 75.6%, respectively. A significant negative correlation was observed between Cys C and PON1 activity (r=-0.42, P=0.010) in NHL patients. Conclusion: This study underscores the potential of Cys C as a biomarker in NHL. Notably, in the multivariable analysis, Cys C was the dominant independent predictor of NHL, with each 1 SD increase in Cys C associated with approximately 11-fold higher odds of NHL. Furthermore, the negative correlation between Cys C and PON1, identified for the first time in patients with NHL, may offer valuable insights into the molecular mechanisms underlying this malignancy.
No takes yet. Share an insight, caveat, or question.
Mirjanić-Аzaric et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: